Porosome Therapeutics announces global drug development partnership with CSIR

image credit- freepik

US-based biotech startup Porosome Therapeutics has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR).

The goals of the partnership include collaboration, co-development and licensing of new and novel drugs. The CSIR announcement highlighted priority domains for collaboration with Porosome: viral infections, Alzheimer's disease, neurological diseases, cystic fibrosis, Type 1 and 2 diabetes, COPD, and lung cancer. 

Porosome Therapeutics has developed a wide range of therapies ranging from small molecules and peptides to biologics that introduce functional porosomes into diseased cells to overcome secretory defects and treat diseases, even reversing them.

In 2025, Porosome Therapeutics announced the determination, for the first time, of the porosome-mediated secretory dysfunction responsible for Alzheimer's Disease.